| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6413499 | ST RENATUS | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic |
Mar, 2020
(4 years ago) | |
| US8580282 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) | |
| US9308191 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) | |
Kovanaze is owned by St Renatus.
Kovanaze contains Oxymetazoline Hydrochloride; Tetracaine Hydrochloride.
Kovanaze has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Kovanaze are:
- US6413499
Kovanaze was authorised for market use on 29 June, 2016.
Kovanaze is available in spray, metered;nasal dosage forms.
Kovanaze can be used as method of anesthetizing at least a portion of the maxillary dental arch.
The generics of Kovanaze are possible to be released after 02 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 29, 2019 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 June, 2016
Treatment: Method of anesthetizing at least a portion of the maxillary dental arch
Dosage: SPRAY, METERED;NASAL
KOVANAZE family patents
